TransMedics Group stock gains 4 percent as analysts see upside
Published on 10/06/2026 at 10:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
TransMedics Group stock (ISIN US89377M1099) was last at USD 82.99 on Nasdaq on October 5, 2026, up 4.00 percent on the session. The move came as analysts continued to assign substantial upside to the organ-transplant technology company, while its next quarterly report is scheduled for October 29, 2026.
Analysts see a wide valuation gap
According to MarketBeat on October 5, 2026, 12 analysts held a consensus rating of Hold, including five Buy, six Hold and one Sell rating. The average 12-month price target was USD 121.10, which places the target 45.9 percent above the October 5 reference price.
The valuation spread is visible against the stock's trading range. At USD 82.99, TransMedics Group stood 46.8 percent below its 52-week high of USD 156.00 and 38.1 percent above its 52-week low of USD 60.10. Market capitalization was USD 2.9 billion, with volume of 994,892 shares on October 5, 2026.
Revenue growth meets margin pressure
The latest reported quarter delivered USD 189.95 million in revenue for Q2 2026, a 20.7 percent year-over-year increase. MarketBeat reported that earnings per share came in at USD 0.44 against a USD 0.50 consensus estimate, while revenue exceeded the USD 184.00 million forecast.
The earnings mix explains the competing signals. Revenue growth remains measurable, but the EPS shortfall and the decline from USD 0.92 in the year-earlier quarter show why the analyst consensus is not uniformly bullish. For investors, execution against the company's growth investments matters as much as the headline sales increase.
Guidance sets the next checkpoint
PR Newswire reported on September 10, 2026, that TransMedics appointed Fernando Araujo as chief financial officer and reiterated 2026 revenue guidance of USD 737 million to USD 757 million. The range represents 22 percent to 25 percent year-over-year growth and excludes revenue from the PAD Aviation investment.
Yahoo Finance lists October 29, 2026 as the next earnings date. That report will give the market a fresh test of the guidance range, the EPS trajectory and the cost of expanding TransMedics' logistics platform.
TransMedics Group stock stays below its high
TransMedics Group stock was last at USD 82.99 on Nasdaq on October 5, 2026, with a 52-week range of USD 60.10 to USD 156.00. The 4.00 percent daily gain contrasts with the stock's 46.8 percent distance from its yearly high.
TransMedics Group stock at a glance
- Company: TransMedics Group, Inc.
- ISIN: US89377M1099
- Ticker: TMDX
- Trading venue: Nasdaq
- Price (as of October 5, 2026, 4:00 p.m. ET): USD 82.99
- Market capitalization: USD 2.9 billion (as of October 5, 2026)
- 52-week range: USD 60.10-156.00 (as of October 5, 2026)
- Sector / Industry: Healthcare / Medical Devices
Upcoming dates for TransMedics Group stock
- October 29, 2026: Third-quarter earnings report
